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Clinical depression and distress are prevalent in cancer patients and are often 
unrecognized by clinicians. However, patient-reported outcomes, or PROs, can facilitate 
provider assessment of oncology treatment plans by detecting depressive and distress symptoms 
early in a patient’s cancer trajectory. Since PROs capture patients’ subjective experience, they 
provide invaluable insight into patient satisfaction, quality of life, and mental health. In April 
2019, leadership at Smilow Cancer Hospital at Yale New Haven Health implemented a new, 
electronic workflow that widely disseminated PHQ-9 and NCCN Distress questionnaires to 
patients seen in three Smilow Cancer Hospital Care Centers. The objective of this pilot study was 
to improve early detection of depression and distress in cancer patients through PROs. 
Prevalence of distress, depression, and self-harm was analyzed across age, sex, race, gender, 
time since diagnosis, and cancer center, and statistically significant differences were validated 
with a chi-square analysis. 18.6% of patients had positive distress and 5.3% had positive PHQ-9 
Scores indicating depression. For those with depression, 1.67%, 1.69%, 0.92%, and 0.34% had 
mild, moderate, moderately severe, and severe depression, respectively. All patients were 
referred to appropriate interventions.  Additionally, an unconditional logistic regression was 
performed to understand significant predictors of self-harm and suicidal ideation. 1.00% of 
patients suffered from suicidal ideation and self-harm.  Moderately severe depression and severe 
depression were statistically significant predictors for self-harm. Moreover, this study recognized 
clinical distress and depression and provided interventions to these patients. Future 
implementation of PROs of distress and depression surveys in cancer patients should consider 
incorporating culturally sensitive questions, acknowledging language barriers, and making 
accommodations for patients with cognitive impairments. 
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There has been a greater emphasis on patient centricity and the patient's role in his or her 
medical care in recent years. Patient centricity is measured through patient-reported outcomes 
(PROs), defined as any report of the status of a patient's health condition that comes directly 
from the patient without interpretation of the patient's response by a clinician or anyone else.1 
Essentially, PROs capture how patients feel about their treatment, well-being, and symptoms. 
PROs have garnered medical providers' attention for their beneficial effects on patient health, 
such as improving quality of life (QoL) and treatment-related side effects.2 Thus, it is 
recommended that PROs be implemented into routine cancer care.  
Compared to its peak in the 1990s, cancer mortality has been steadily decreasing in the 
United States due to advancing medical treatments and early cancer screening programs, leading 
to improved survivorship in cancer patients.3 Cancer mortality has decreased continuously from 
1991 to 2018 for a total decline of 31%, translating into 3.2 million fewer cancer deaths.4 Given 
that most cancers have transitioned from acute, life-threatening diseases to chronic ones, there 
has been growing concern with the application of PROs, such as distress and depression 
screenings, to improve post-cancer care since prolonged cancer prognosis does not necessarily 
equal better QoL. Although distress and depression screenings have been validated and widely 
disseminated in family care practices5, the uptake of screening tools for the psychological care 
and intervention of oncology patients has not been fully integrated into most cancer centers. 
Hence, to improve oncology care, payers have implemented hospital mandates to screen for 
distress and depression in cancer patients to improve health and alleviate costs6. 
Given that the 5 year-relative survival from cancer is 67.4%, approximately 25% of 
cancer patients suffer from clinical depression after receiving a cancer diagnosis, fearing death, 
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recurrence, and treatment side effects.7 Unfortunately, clinicians often dismiss serious, 
depressive symptoms in cancer patients, assuming sadness and depression are part of the normal, 
emotional repertoire of oncology patients.8 Although it is expected for cancer patients to feel 
saddened about their diagnosis, clinical depression and distress are categorically different from 
temporary sadness and require immediate psychological intervention.9 Sadness is a normal 
human emotion that fluctuates over time and can be appropriately managed with strong family 
support and/or lifestyle changes; however, cancer patients suffering from clinical depression 
suffer from physical and psychological symptoms that significantly impair their quality of life 
for a prolonged period.10 About 70% of depressed cancer patients do not receive appropriate 
help, and only 5% of patients consult a medical professional.11 Suicide risk in cancer patients is 
four times higher than in the general population, and this risk is the highest in the first year of 
diagnosis.12 Moreover, the incidence of suicide death in cancer patients was 39.72 per 100,000 
person-years.13 Therefore, PROs are crucial for detecting depression and distress in a timely and 
accurate manner so that patients’ QoL and survivorship improves. PROs also glean incredible 
insight on how depression and distress scores, as well as important factors like cancer subtype, 
age, sex, and gender, may affect a patient’s thought of self-harm throughout his or her cancer 
trajectory. Hence, if appropriately utilized, PROs of distress and depression screenings could 
improve cancer patients' mental health by referring them to social workers, psychologists, or 
psychiatrists for appropriate interventions and offer holistic patient-centric care. 
The driving motivation for collecting PROs in oncology patients stems from the Center 
for Medicare and Medicaid Innovation (CMMI) incentivizing distress and depression screenings 
in routine medical care via the oncology care model (OCM), a program that improves patient 
health while minimizing healthcare expenditures.14 OCM encourages a multidisciplinary 
8 
approach to healthcare by mandating the use of social workers, who can assist cancer patients in 
an array of supportable services like financial and nutritional support. Among the 13 care 
components enlisted by the OCM framework, two of them require the involvement of social 
work services: Advance care plans and Distress and Depression screening.15 The latter mandate 
encourages clinicians to address patients' psychosocial health needs in a holistic manner while 
ensuring cancer patients are receiving necessary help. Ultimately, OCM is a payment model that 
tethers financial rewards to provider accountability and proper cancer patient management. The 
OCM framework incentivizes systematic efficiency in care centers by providing additional 
payments in 6-month increments for each active cancer patient and encouraging a savings 
program for chemotherapies and drugs if overall costs are lowered.14 
As of January 2020, 138 practices are participating in OCM, with the Smilow Cancer 
Hospital at Yale-New Haven Health (YNHH) being one of the four participating care centers in 
Connecticut.16 Within the Smilow Cancer Hospital, the OCM performance metric accounts for 
the number of patients appropriately screened and followed up within 24 hours, which results in 
bonus payments—this Pay for Performance model rolled-out in January 2019. Thanks to these 
financial incentives, cancer care centers within the YNHH network have piloted the collection of 
distress and depression PROs within the electronic medical record workflow.  
Prior to the initiation of this new electronic PRO process in 2018 at Smilow Cancer 
Hospital and Care Centers, depression and distress screening had low compliance rates due to a 
lack of standardized workflow. Screenings were done on paper, not collected from all patients, 
and were not patient-reported. In turn, compliance rates for completed the surveys were low: 
26% for depression screening and 40% for distress. Additionally, depression and distress 
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screenings were not patient-reported since the depression and distress questionnaires were 
completed by an OCM Care Coordinator and a nurse, respectively.  
The purpose of this study was to determine the feasibility of implementing the distress 
and depression PROs via the electronic medical record in three Smilow Cancer Hospital Care 
Centers and examining differences in depression and distress by various demographic and 
clinical characteristics. These analyses will provide preliminary results of feasibility, rates of 
depression and distress, and referrals for treatment. These findings will provide necessary 
information for disseminating and implementing these PROs and improving early detection of 
depressive and distress symptoms. 
 
Methods:  
Overview of Project 
In November 2018, we conducted a pilot program that electronically screened all 
ambulatory cancer patients for distress and depression symptoms at three Smilow Cancer 
Hospital Cancer Care sites: The Smilow Cancer Hospital Breast Center, Guilford Care Center, 
and the Care Center at Torrington. The study was conducted in multiple phases, with a 
preparatory phase beginning in November 2018 and the remaining two phases of roll-outs 
beginning in April 2019 and August 2019. Smilow Breast Center and Guilford went live in April 
2019, and Torrington Care Center followed in August 2019. The study continued until March 
2020. At these study sites, patients completed the PHQ-2 and PHQ-9 surveys and Distress 
Thermometer screening on iPads while in the waiting room, who were then alerted in real-time 
by providers regarding referrals and interventions. Also, in compliance with the new Joint 
Commission mandate, the YNHH screen policy implemented the Columbia Suicide Severity 
Rating Scale (CSSRS) to assess patients with suicide ideation. 
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Patients 
The scope of the program included all adult patients diagnosed with cancer who were 
seen for a clinic visit at Smilow, Guilford, and Torrington Care Centers. Patients who were seen 
for imaging or procedure visits were not assigned the surveys.    
 
Data Collection 
Information on patient age, sex, race, gender, diagnosis dates, PHQ-9, PHQ-2, and 
distress scores were collected from EPIC electronic medical records provided by the JDAT team 
at Yale New Haven Health. 
 
PHQ-2, PHQ-9 and CRRS Questionnaires 
The PHQ-2 is a 2-question survey that acts as the first-line approach for depression and 
anhedonia screening over the past two weeks.17 The PHQ-2 score ranges from 0-6: If a patient 
scores a 3 or higher, then a major depressive episode may likely occur. Patients who screen 
positive for depression should complete the PHQ-9 to determine if they are at risk for a 
depressive disorder.17 However, if the patient scores a 3 or less on the PHQ-2 survey, the patient 
has a negative depression score which does not necessitate an intervention (Figure 1). 
The PHQ-9 is a 9-question survey that measures depression severity, with the first two 
questions stemming from the PHQ-2. Scores of 1-4, 5-9, 10-14, 15-19, and 20-27 act as 
thresholds for minimal, mild, moderate, moderately severe, and severe depression, respectively.18 
Minimal depression does not necessitate an intervention. The last question on the survey screens 
for suicide risk and self-harm, which requires emergency assessment and intervention. This 
question asks: "Thoughts that you would be better off dead or thoughts of hurting yourself in 
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some way?" If patients answer with "several days", "more than half the days", or "nearly every 
day", then they must remain in the clinic and have a social worker evaluate them with the 
Columbia Suicide Severity Rating Scale (CSSRS).19 The CSSRS is an evidence-based tool that 
assesses suicidal ideation. For patients who screen positive for suicidal ideation (moderate or 
high) then a suicide risk assessment is done by a healthcare provider or a social worker, who then 
asks about the patient's plan, intent, or self-harm behaviors. If the patient is considered high risk 
of suicide, a healthcare provider, social worker, or nurse must stay with the patient until he or she 
is transferred to the emergency department (Figure 1).  
Under the "Preventive Care and Screening: Screening for Depression and Follow-Up 
Plan" of the Oncology Care Model, a percentage of cancer patients 18 years and older who were 
screened for depression every 6 months upon their first encounter and if screened positive, 
should pursue follow up. Follow-up plans include suicide risk assessment, referral to a 
practitioner for the treatment of depression, pharmacological interventions, and more.20 
 
The National Comprehensive Cancer Network (NCCN) Distress Thermometer 
Distress is measured through the National Comprehensive Cancer Network (NCCN) 
Distress Thermometer, an evidence-based tool that helps providers provide support to oncology 
patients.21 The tool measures distress from a score of 0-10, and if patients report a score greater 
than or equal to four, which indicates moderate to extreme distress, clinical judgment is required, 
and a physician will be notified of the score. If the patient scores a 4 or lower on the NCCN 
distress questionnaire, the patient has negative distress and does not require an intervention; 
however, if a distress score of 4 or more is recorded, then based on the score on the Distress 
Screening tool, referrals could be made to a social worker, chaplain, nutritionist, or psychiatrist.22  
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(Figure 1). Although distress screening must be assessed at a minimum of one time, all patients 
should be screened at every medical visit. If this is not possible, patients should be screened at 
their first visit and at appropriate, timely intervals per the NCCN guidelines.23 Also, according to 
the Commission on Cancer, all cancer patients must be screened for distress a minimum of once 
per pivotal medical visit as determined by the program.24 
 
Current Workflow 
When a patient arrives at check-in, the staff determines if they need to complete distress 
and depression surveys based on their department-appointed reported visit or DAR. 
Questionnaires are administered on the first visit and then every 90 days after the initial visit. 
Staff at the front desk are trained to answer questions patients may have regarding the screening 
program, such as “Who will receive the results?” and “What is this used for?” If asked these 
questions, the staff will answer “Your Smilow care prover team”, and “To better meet your 
physical and emotional needs'', respectively.  Once they agree to complete the screening, the 
patient completes the Distress Screening and PHQ-2 on the iPad; if the patient screens positive 
on the PHQ-2 survey, then they will complete the PHQ-9. If the patient refuses to answer the 
questionnaire, the front desk will document it through the DAR. Options for non-participation 
include language barriers, technology issues, lack of an iPad, and general refusal. If the distress 
and depression screenings are negative (distress ≤ 4  and PHQ-2 < 3), the results are filed and no 
intervention is necessary. If the screening is positive (distress ≥ 4 and/or positive PHQ-2 ≥ 3), 
then the system notifies the provider to review the results in EPIC through the best practice 
advisory (BPA), which are reminder tools within EPIC electronic health records that provide 
clinical decision support. Once alerted of positive depression and/or distress scores by the BPA, 
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the provider will document an action plan and talk to the patient. Referral options under EPIC 
include: “Referral to Social Work”, “Referral to Psychiatry”, and “Referral to Psychology''.  
Other action plans may not require referral but instead include: continued care with an existing 
mental health provider, discussing pertinent distress symptoms and providing counseling, and 
reviewing and adjusting medications. BPA will notify the provider if the patient has answered 
the self-harm question with an exclamation mark. Depression scores that are considered 
moderately severe and severe are also represented with a bright, yellow icon.  If the patient has a 
positive self-harm response, then either a social worker or a nurse will stay with the patient until 
the patient is transferred to the Emergency Department (Figure 1).  
 
Data Analysis  
Statistical analyses were conducted with the SAS 9.4 statistical software. Baseline data 
were stratified on variables such as age, sex, race, cancer center, time since cancer diagnosis, and 
cancer type. Since the PHQ-9 and the distress questionnaire allowed patients to input exact, 
numerical responses to all questions, we based each category of depression and distress criteria 
on appropriate thresholds for validated score ranges: For example, depression and distress scores 
were categorized into their appropriate criteria (minimal, mild, moderate, moderately severe, and 
severe depression and negative and positive distress, respectively) and were descriptively 
analyzed as categorical variables across all previously mentioned covariates. The threshold for 
the variable, “time since a patient's first cancer diagnosis”, was determined at six months since 
the onset of the COVID-19 pandemic terminated data collected after 11 months. Hence, all 
patients in the sample did not have a period of 1-year post initial cancer diagnosis. Statistical 
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comparisons of categorical depression and distress scores were performed with the Fisher Exact 
test with a Monte Carlo simulation.  
For analytical purposes, the characteristic “Referral to Social work”, was categorized as a 
dichotomous variable with two outcomes: Patients referred to social work or treated with a 
different intervention. As a variable, “Referral to Social Work” encompassed numerous related 
treatment options, which included, “Referral to Social work; Discussed pertinent distressing 
symptoms and provided counseling”, “Medications reviewed and added or adjusted as needed; 
Referral to Social work”, and simply, “Referral to Social work”. Social work was an intervention 
of interest to the study since OCM purports the need for integrated, multidisciplinary cancer care 
that includes psychosocial work plans produced by social workers.  
We used simple and multivariate unconditional logistic regression models to identify key 
exposure variables and predictors on the binary outcome of self-harm. The primary exposure 
variables were categorical scores of depression. Key covariates included age, sex, race, cancer 
center, time since cancer diagnosis, cancer type, and distress scores. The binary outcome of self-
harm was split into two categories depending on the patients’ answer to the last question of the 
PHQ-9 questionnaire—"Thoughts that you would be better off dead, or thoughts of hurting 
yourself in some way?"—and their respective PHQ-9 score. If the patient scored a 0 on the last 
PHQ-9 question, then they were not at risk of self-harm or suicide; however, if an individual 
answered a 1, 2, or 3, then the patient was considered high-risk of self-harm and suicidal 
thoughts. The reference categories for age, sex, race, cancer center, time since cancer diagnosis, 
cancer type were patients aged 25-44 years old, males, White or Caucasians, Smilow Breast 
Cancer Center, patients with less than six months since cancer diagnosis, and all other cancers, 
respectively. The reference variables for depression and distress criteria were negative 
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depression and negative distress, respectively.  Discovery modeling was performed in a 50% 
split of the total sample, creating two randomly assigned discovery and validation datasets 
compared across selected parameter estimates to test for equivalence, reliability, and external 
validity. The sensitivity and specificity were also determined for each multivariate regression 
model. Additionally, the goodness of fit of each multivariate logistic model was estimated with 
the Hosmer-Lemeshow test.  
 
Results:  
Characteristics of Patients  
A total of 6,192 patients from Smilow Breast Cancer Center, Torrington Care Center, and 
Guilford Care Center were part of the study from April 2019 to March 2020, with 49.3% of 
patients from Smilow, 21.3% from Torrington, and 29.3% from Guilford. The mean age was 
66.8 + 13.0 years, and 81.7% of participants were women (Table 1). There were more females 
than males in the sample; more than half of the participants were admitted to Smilow, where 
98.9% of survey respondents were female.  The most common reasons for non-participation in 
the distress and depression screenings included language barriers, technology issues, and general 
refusal. Therefore, 5,396 patients completed the distress survey, and 5,576 patients completed 
the PHQ-9 questionnaire. The top six most reported cancer subtypes across all three cancer 
centers were: Breast cancer, chronic lymphocytic leukemia, malignant melanoma, prostate 
cancer, myeloma, and colon cancer. These six cancer subtypes accounted for 64.8% of all 
reported cancers. The most reported cancer subtype was breast cancer, which accounted for 
55.5% of all cancer diagnoses. 82.6% of all participants were White, and most patients were 
diagnosed within the past 6 months, with 11.5% diagnosed more than 6 months prior (Table 1).  
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Distribution of Depression Scores 
The mean and median score of the total PHQ-9 score was 0.81 + 2.73 and 0, respectively. 
Outcomes for each survey were skewed to the right since the majority of patients reported low 
scores of 0 or 1 on the PHQ-9 survey: 79.2% of study participants had a total PHQ-9 score of 0. 
The highest reported depression score was 27 with a cumulative frequency of 0.04%. Also, 
16.1%, 1.67%, 1.69%, 0.92%, and 0.34% of cancer patients were in the minimal, mild, moderate, 
moderately severe, and severe categories of depression, respectively. (Table 2)  
A total of 94.7% of study participants had a PHQ-2 score < 3, which does not require an 
intervention from the provider (Table 2 and 3). The remaining 5.30% of participants scored a 3 
or higher on the PHQ-2 survey and had to complete the PHQ-9, which necessitated intervention. 
(Table 2). 52.6% of patients aged 45-64 and 36.8% of patients aged 65-84 reported severe 
depression compared to 10.5% of 25-44 year olds and 0% of 85+ year olds with severe 
depression (p-value=<0.001). Additionally, 78.9% of females reported severe depression 
compared to 21.1% of males (p-value=<0.001) with severe depression. 47.4% of patients with 
breast cancer were severely depressed compared to 5.26% with myeloma and 47.4% with other 
cancer types who were severely depressed (p-value=<0.001). 84.2% of patients with less than 6 
months since diagnosis reported serve depression compared to 15.8% of patients with more than 
6 months since diagnosis who were severely depressed. (p-value=<0.001). (Table 5) 
 
Distribution of Distress Scores 
The mean and median score of the distress survey was 1.79 + 2.32 and 1.00, respectively 
(Table 4). Similar to the non-parametric distribution of depression scores, most of the distress 
were skewed to the right: 45.3% of participants had a total distress score of 0. Furthermore, 
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81.4% of cancer patients had a negative distress score (distress ≤ 4). Additionally, 18.6% of 
patients reported positive distress scores. The highest reported distress score was a 10 with a 
frequency of 0.73%. (Table 3)  
 48.9% of patients who were 45-54 year olds reported positive distress compared to 7.41% 
of patients aged 25-44 year olds, 39.2% of patients aged 65-84 year olds, and 4.50% of patients 
who were 85+ year olds with positive distress. There were 89.7% females who reported positive 
distress scores compared to 10.3% males with positive distress. Additionally, 85.0% of patients 
who were White had positive distress compared to 5.52% patients who were Black or African 
American, 1.91% of Asian patients, 3.20% of other races, and 4.34% of patients who refused to 
disclose their race with positive distress (p-value=<0.001). There were 30.8% breast cancer 
patients who reported positive distress compared to 30.8% patients suffering from other cancer 
types, 1.50% chronic lymphocytic leukemia patients, 1.30% malignant melanoma patients, 
0.50% prostate cancer patients, and 0.10% colon cancer patients with positive distress. There 
were 87.1% of patients with less than 6 months since their cancer diagnosis who had positive 
distress compared to 12.9% of patients more than 6 months since their cancer diagnosis with 
distress. There were 68.2% of patients seen at Smilow Breast Cancer Center with positive 
distress compared to 10.0% and 21.8% of patients to Torrington and Guilford with positive 
distress, respectively. (Table 6) 
 
Distribution of Referral to Social Work 
 In total, there were 192 patients who were referred to social work per OCM 
recommendations, which comprised 15.2% of all interventions administered for distress and 
depression. Moreover, all 257 patients who were at risk of depression and/or 999 patients at risk 
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of distress were referred to appropriate interventions, which included, “Counseling provided to 
patient, no mental health referral required”, “Medications reviewed and added or adjusted as 
needed”, and “Continue care with existing mental health provider; Discussed pertinent 
distressing symptoms and provided counseling”. Therefore, there was a 100% intervention rate 
in this program.  
 
Reports of Positive Self-Harm   
In total, 62 oncology patients had positive self-harm responses, which comprised 1.00% 
of the total sample. Out of the 712 patients who answered the last question on the PHQ-9, 8.71% 
of patients tested positive for self-harm. Positive self-harm scores were reported across all 
depression and distress criteria and recorded across all age groups, sexes, races, cancer centers, 
times since cancer diagnosis, and cancer types. Additionally, 33.3%, 20.4%, and 12.8% of 
patients with severe, moderately severe, and moderate levels of depression reported positive self- 
harm scores. Also, 14.1% of patients with positive distress reported positive self-harm scores. 
Patients with the highest frequency of positive test scores were aged 25-44 (14.8%). Also, 10.5% 
of males had positive self-harm scores compared to 8.10% of females. (Table 7) 
 
Unconditional Logistic Regression Analysis  
The simple, unadjusted logistic regression model looked at each predictor variable 
separately and analyzed their individual effects on self-harm. For the unadjusted logistic 
regression model, the parameter estimates were similar for the discovery and validated models, 
and the parameter estimates for the validated model were reported. Hence, the unadjusted model 
is a reliable predictor of self-harm. 
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The multivariate analysis was also conducted for both discovery and validation datasets 
as well as sensitivity and specificity analyses. However, the groups were discrepant in terms of 
the key predictors selected in their respective stepwise, multivariate logistic regression models. 
The discovery model selected for patients who refused to disclose their race, people of other 
races, patients aged 45-64, patients with positive distress, and patients with prostate cancer; 
however, patients of other races were not a significant predictor in the stepwise regression for the 
discovery model. Meanwhile, the validated model selected for female patients, patients seen at 
Guilford, patients seen at Torrington, patients with prostate cancer, and patients suffering from 
severe and moderately severe depression. In the discovery regression model, prostate cancer is 
more correlated with the outcome and had a significant p-value; however, in the validated 
stepwise regression model, prostate cancer was a not statistically significant predictor (p-
value=0.06) of self-harm.  Additionally, In the validated stepwise logistic regression model, the 
p-value was not statistically significant for female patients (p-value=0.13) and was not 
statistically significant for patients seen at Torrington (p-value=0.14). Since the selected 
variables and the parameter estimates for the discovery and validation dataset were different, the 
validated model should be interpreted with caution. 
The p-value for the Hosmer and Lemeshow test was 0.87 for the validated model, 
meaning that we can reject the null hypothesis and conclude that the model accurately predicts 
the probability of self-harm. However, the stepwise logistic regression for the validated dataset 
may not indicate the model’s reliability to predict self-harm due to the discrepant parameter 
estimates observed during the discovery modeling.  
Both the validation and discovery data tests had high specificity and low sensitivity 
values. The specificity, or the true negative rate, is the proportion of true negative responders to 
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the self-harm question who had a negative result on the last question on the PHQ-9 survey. The 
specificity for the validated and discovery models were 99.4% and 100%, respectively. On the 
other hand, the sensitivity, or the true positive rate, is the proportion of true positive responders 
who had a positive result to the last question on the PHQ-9. The sensitivity for the validated and 
the discovery models were 11.8% and 0.00%, respectively. The parameter estimates of 
sensitivity and specificity are different in both models. However, if only considering the 
validated dataset, the multivariate regression model was able to identify a positive result for 
11.8% of people suffering from harmful or suicidal thoughts and find a negative result for 99.4% 
of patients who did not suffer from self-harm or suicidal thoughts. 
In the validated, multivariate stepwise logistic regression, the statistically significant 
predictors were patients seen at Guilford, patients suffering from severe depression, and patients 
with moderately severe depression. Compared to patients seen at Smilow and Torrington, 
patients seen at Guilford had 0.17 lower odds (CI: 0.05-0.66) of reporting a positive self-harm 
response. Compared to patients with minimal, mild, moderate depression, patients with 
moderately severe depression had 3.72 (CI: 1.24-11.2) higher odds of reporting self-harm. Also, 
compared to patients with minimal, mild, moderate depression, patients with severe depression 
had 8.23 (CI: 1.72-39.3) higher odds of reporting self-harm. (Table 8)  
 
Discussion:  
 This analysis examined the prevalence of depression and distress scores in oncology 
patients who participated in the new, electronic workflow piloted by Smilow Cancer Hospital. 
This analysis also identified predictors for self-harm and suicidal thoughts as an effort to 
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understand if this outcome is predicted by depression while considering key covariates like age, 
sex, race, cancer center, time since cancer diagnosis, distress, and cancer type. 
 Although the majority of patients reported negative depression and distress scores, it is 
imperative to focus on patients who reported positive distress and PHQ-9 scores since they 
require timely and immediate action plans from providers. Previous meta-analyses have 
indicated variability in prevalence rates of depression that range from 0% to 46% for cancer 
patients.25 In this study, 81.4% of patients reported negative distress. Moreover, 94.7% of 
patients reported negative depression since their PHQ-2 score was less than 3—this also includes 
the depression criteria for minimal depression (PHQ-9 score between 1-4), which does not 
necessitate provider intervention. 18.6% of patients had positive distress, and 5.30% had positive 
PHQ-9 Scores indicating depression. For those with positive PHQ-9 scores, 1.67%, 1.69%, 
0.92%, and 0.34% had mild, moderate, moderately severe, and severe depression, respectively. 
According to existing literature, prevalence estimates for major depression—which includes 
moderate, moderately severe, and severe depression—and minor depression—which includes 
mild and minimal depression—are 15% and 10% in cancer patients, respectively.26 In this 
program, 2.95% had major depression, and 17.8% had minor depression. Although this study had 
lower rates of major depression and higher rates of minor depression, it is crucial to prioritize 
patients with moderate, moderately severe, and severe depression since it has been indicated that 
major depression can lead to worse outcomes.  
 Patients who comprised the highest percentages of severe depression were patients aged 
45-64 years old, were females, were White, and had breast cancer. Previous literature suggests 
that depression is most common in pancreatic and lung cancers8; however, breast cancer patients 
in our study had the highest frequencies of depression across all depression criteria. This finding 
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could be attributed to the fact that 98.9% of patients who completed the distress and depression 
surveys at Smilow Breast Cancer were women. Since most of the sample was comprised of 
female breast cancer patients, future studies should examine a more diverse sample. 
 Previous work has indicated that mental illness is a key predictor of suicidality in cancer 
patients and that a strong relationship exists between depression and suicide risk.13  In fact, more 
than 90% of people who committed suicide have depression or another underlying mental 
illness.27  Previous work indicated that depressive episodes, pain, and a lack of social network are 
root causes for suicide ideation in cancer patients.28 In our study, the multivariate regression 
model indicated that patients who were at risk of self-harm and suicidal thoughts were those with 
prostate cancer, patients with severe depression, and patients with moderately severe depression. 
Compared to negative, minimal, mild, and moderate depression, the odds ratio of reporting self-
harm scores was 3.72 (CI: 1.24-11.2) for moderately severe depression and 8.23 (CI:1.72-39.3) 
for severe depression. Although these findings correspond with current literature regarding 
depression as a risk factor for suicide, they do not account for other important factors such as 
poor social support, hopelessness, advanced cancers, and delirium on self-harm risk.28 Moving 
forward, Smilow Cancer Hospital should consider the effects that moderately severe and severe 
depression have on self-harm and encourage providers to recognize the importance of 
maintaining a supportive rapport with patients while treating major depressive symptoms 
appropriately. The multivariate regression model indicated that the last question on PHQ-9 had a 
high specificity (99.4%) and lower sensitivity (11.08%), implying that the last question, 
"Thoughts that you would be better off dead, or thoughts of hurting yourself in some way?", was 
able to detect true negative responders given depression as the primary exposure. Current 
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literature notes that the diagnostic sensitivity of PHQ-9 scores >10 has a sensitivity of 88%, but 
more research is needed regarding the diagnostic validity of the last question.29  
 When tethered with depression screening, routine distress screening of cancer patients 
can improve overall care when accompanied with psychosocial treatment. Previous studies 
indicated that 25-30% of newly diagnosed cancer patients have high levels of distress.30 In our 
study, 87.1% of cancer patients diagnosed in the past 6 months had a positive distress score 
compared to 12.9% of cancer patients with more than 6 months since their initial diagnosis. 
Hence, it is critical for physicians to appropriately refer these patients to holistic, patient-centric 
treatment options like social workers. Social workers are essential for addressing numerous 
psychosocial interventions and are at the forefront of developing plans that pinpoint patients’ 
distress.   
Although patients may have a negative distress score or a negative depression score, they 
could still be at risk of self-harm and suicidal thoughts. Our results indicate that 5.58% of 
patients with negative distress and 8.11% of patients with minimal depression had positive self-
harm responses. To that extent, depressive symptoms, even mild ones, can still deleteriously 
impact a patient's cancer trajectory and decrease their quality of life, ultimately contributing to 
suicide.13 Moreover, incident depression holds tremendous clinical value in early detection of 
suicide and therefore should not be overlooked by providers.13 Studies have also indicated that 
actual suicide rates are higher in men than in women31, which shed insight into the reported 
frequencies of positive self-harm by males and females in cancer patients, which were 10.5% and 
8.10%, respectively. Previous findings have also indicated that the first six months after a cancer 
diagnosis is an incredibly stressful period that can increase the risk of suicide in cancer 
patients.32 Unsurprisingly, 87.1% of Yale cancer patients with less than 6 months since their 
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diagnosis suffered from positive distress compared to 12.9% of Yale cancer patients with more 
than 6 months since diagnosis. However, the difference in self-reported self-harm scores was 
marginally different between patients who had less than 6 months since diagnosis (7.73%) versus 
patients who had more than six months (8.95%). Previous work has indicated that suicide rates in 
cancer patients decrease years after diagnosis; nevertheless, it is imperative that physicians 
adequately assess suicidal tendencies during the early, critical period of elevated suicidal 
ideation.13 Although physicians may not be able to prevent the chronic medical effects of cancer, 
they have a responsibility to prevent psychological and psychosocial fall-out. Hence, early 
depression and distress screenings and effective treatments are critically important for reducing 
the cost associated with cancer and improving cancer patients’ quality of life.    
Additionally, previous meta-analyses have indicated that patients with prostate cancer 
have significantly higher suicide rates per 100,000 person-years compared to other cancers, 
which parallels the high percentage of patients with prostate cancer (44.4%) reporting positive 
self-harm in this study.33 Existing literature has also indicated that patients who have been 
diagnosed with prostate, lung, colon, and breast cancer were also more likely to report positive 
scores of self-harm.34 In our study, 4.00% of patients with colon cancer, 8.68% of patients with 
breast cancer, 4.00% of patients with myeloma reported positive scores of self-harm. 
Additionally, 6.25% of Yale patients with chronic lymphocytic leukemia and 8.23% patients 
with other cancers also reported positive self-harm scores. Existing literature demonstrated that 
patients with breast cancer had an elevated risk of suicidality compared to patients with other 
cancers and that elderly men with prostate cancer and men with myeloma were also at increased 
risk of self-harm.35 In a prospective study carried out in cancer patients in the UK, patients who 
reported thoughts of self-harm were significantly younger than the rest of the cohort.34 Similarly, 
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14.8% of Yale cancer patients aged 25-44 years old reported positive self-harm scores, which 
was higher than the reported positive self-harm scores by 45-64 year olds (6.46%), 65-84 year 
olds (8.75%), and patients 85+ years of age (11.5%). Ultimately, future studies at Yale New 
Haven Health should also gauge the impact of chronic lymphocytic leukemia on self-harm as 
well as other social factors, such as marital status, religious beliefs, and family support on suicide 
risk.  
The study’s greatest strength was its ability to refer everyone at risk of depression and 
distress to appropriate interventions. The EPIC workflow and the BPA notification system 
enabled physicians to create action plans when notified of a positive depression and/or distress 
score through the electronic workflow. Furthermore, the Oncology Care Model encouraged the 
use of social work to treat numerous facets of patients’ emotional and psychosocial repertoire. 
15.2% of patients who received interventions were referred to social work; although some action 
plans may not elicit the help of a social worker, it is important that physicians recognize the 
importance of social workers in the multidisciplinary framework of medicine and the social 
worker’s role in improved health outcomes. Additionally, the brevity of both the distress and 
depression surveys assures greater completion of data while reducing participant fatigue. As 
such, the electronic surveys were quick and straightforward to fill out, taking approximately 5 
minutes to complete.  
 There are several limitations regarding the study’s design and timeframe. Given that this 
study was a pilot program implemented for a short period of 11 months, data regarding follow-
ups and the effectiveness of specific psychological or lifestyle interventions were not collected. 
In the same regard, data on lower total scores of PHQ-9 or distress do not exist, and conclusions 
cannot be drawn on the overall effectiveness of the standardized, electronic workflow for 
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depression and distress. Also, the program was primarily composed of White women, which 
affects the generalizability of these findings.  
Every participant has a vital role to play in improving patient health efficiently and 
effectively. Although PROs are helpful in clinical management, it has been challenging to 
implement in clinical settings: Time, expenses, and adequate assessment measures are several 
significant burdens preventing the widespread use of PROs in routine healthcare practice. When 
considering PRO implementation programs, it is crucial to monitor and adjust for these caveats 
and setbacks, especially within their early phases. Factors affecting the implementation of these 
PROs include overwhelmed physicians, technology and software issues, confusion about the 
workflow, and lack of resources for positively screened patients. Additionally, patients who 
completed the questionnaires experienced several pros and cons with the new electronic 
workflow. Patients also voiced a preference for the iPad over paper since the latter method was 
tedious, burdensome, and required interpretation of a nurse practitioner. In the future, special 
circumstances should be considered in the assessment of distress and depression, such as cultural 
sensitivity, language barriers, and provisions for people with cognitive impairments.   
Looking forward, the leadership at Smilow Cancer Center should consider collecting 
PRO data as frequently as possible without overburdening patients. In the case of the PHQ-
2/PHQ-9 and distress questionnaires, the overarching goal of this new electronic workflow is to 
understand if a patient’s depression and/or distress changed from baseline to a future point in 
time after administration of a particular intervention. Unfortunately, as of December 2019, the 
SARS-CoV-2 pandemic has temporarily halted this new electronic screening program. Once 
Smilow Cancer Hospital reinitiates this pilot study, leadership at Yale New Haven Health can 
assess if PROs and provider interventions and action plans improved patients’ distress and 
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depression symptoms.  Moreover, it is important to employ personnel who can help patients 
complete the distress and depression surveys to increase compliance and reduce missing data 
without influencing their response.   
Furthermore, the SARS-CoV-2 global pandemic has emphasized the need for PROs and 
precision medicine for cancer patients: the onslaught of a severe, contagious respiratory illness 
has increased the need for telemedicine and remote monitoring of patients. As patients become 
further removed from their physicians, patient-centric care carries more importance; therefore, 
clinicians need to administer appropriate interventions despite resource constraints so that cancer 
patients can improve their distress and depression symptoms. Consequently, cancer hospitals 
should incorporate PROs for distress and depression screening in electronic questionnaires that 
can be done at home to assess for mental health during these troubling times. 
In sum, PROs are incredibly important for improving quality of life since physicians may 
mistakenly dismiss severe depressive symptoms as normal emotional responses to cancer. PROs 
can address the issue of therapeutic nihilism, which prevents clinicians from differentiating 
clinical depression from normal sadness. The electronic screening workflow is the right step 









List of Tables: 
Table 1: Patient Baseline Characteristics (N=6,192) 
Characteristic Na N% 
Age (years), mean+ SD 66.8 + 13.0   
Sex     
         Male          1264  18.3% 
        Female           5656 81.7% 
Race   
        White or Caucasian  5715 82.6% 
       Black or African         
American  432 6.24% 
        Asian 133 1.92% 
        Other 268 3.87% 
        Patient Refused 372 5.38% 
Cancer Type    
         Breast Cancer  3843 55.5% 
        Chronic lymphocytic 
leukemia  196 2.83% 
       Malignant Melanoma 123 1.78% 
       Prostate Cancer  126 1.82% 
       Myeloma 101 1.46% 
       Colon Cancer  93 1.34% 
29 
    Other cancers  2439 35.2% 
Time Since Diagnosis   
       More than 6 months 
since diagnosis  795 11.5% 
       Less than 6 months 
since diagnosis 6126 88.5%  
Site    
       Smilow 3414  49.3% 
       Torrington  1477 21.3% 
       Guilford 2030 29.3% 
 
 
Table 2: Distribution of PHQ-9 Scores (N=5,576) 
Characteristic Na N% 
PHQ-9 Scores, mean+ 
SD 0.81 + 2.73  
PHQ-Scores   
0 4417* 79.2%* 
1          421* 7.55%* 
2          441* 7.91%* 
3 18 0.32% 
4 19 0.34% 
5 20 0.36% 
30 
6 20 0.36% 
7 23 0.41% 
8 12 0.22%  
9 18 0.32% 
10 19 0.34% 
11 21 0.38% 
12 20 0.36% 
13 14 0.25% 
14 20 0.36% 
15 11 0.20% 
16 16 0.29% 
17 11 0.20% 
18 9 0.16% 
19 4 0.07% 
20 5 0.09% 
21 6  0.11% 
22 3 0.05% 
23 2 0.04% 
24 3 0.05% 
31 
25 0 0.00% 
26 0 0.00% 
27 2 0.04% 
Categories of 
Depression    
No depression  4417 79.3%* 
Minimal           899 16.1%* 
Mild            93 1.67% 
Moderate  94 1.69% 
Moderately Severe  51 0.92% 
Severe  19 0.34% 
   *Also equivalent to a PHQ-2 score less than 3 
 
 
Table 3: Distribution of Distress Scores (N=5,396) 
Characteristic Na N% 
Distress Scores, mean+ 
SD 1.79 +2.32  
Distress Scores    
0 2435 45.3% 
1          717 13.4% 
2           681 12.7% 
3 539 10.0% 
32 
4 247 4.60% 
5 253 4.71% 
6 143 2.66% 
7 160 2.98% 
8 114 2.12%  
9 43 0.80% 
10 39 0.73% 
11 0 0.00% 
12 0 0.00% 
13 0 0.00% 
14 0 0.00% 
Categories of Distress    
Negative Distress  4327 81.4% 




Table 4: Referral to Social Work (N=192) 
Characteristic Na N% 
Referral Rate    
    Social Work  192 15.2% 
33 
    Other interventions  1064 84.8% 
Age (years)    
       25-44 26 13.5% 
       45-64 93 48.4% 
        65-84 72 37.5% 
        85+ 1 0.52% 
Sex     
         Male          17 8.85% 
        Female           175 91.2% 
Race   
        White   128 78.5% 
       Black or African         
American  15 9.20% 
        Asian 4 2.45% 
        Other 8 4.91% 
        Patient Refused 8 4.91% 
Cancer Type    
         Breast Cancer  126 65.6% 
        Chronic lymphocytic 
leukemia  0 0.00% 
       Malignant Melanoma 1 0.52% 
       Prostate Cancer  0 0.00% 
34 
       Myeloma 0 0.00% 
       Colon Cancer  2 1..04% 
    Other cancers  63 1.04% 
Time Since Diagnosis   
       More than 6 months 
since diagnosis  47 24.5% 
       Less than 6 months 
since diagnosis 145 75.5% 
Site    
       Smilow 151 78.7% 
       Torrington  21 12.5% 
       Guilford  17 8.85% 
Depression Scores   
        Severe  5 2.60% 
        Moderately Severe  13 6.77% 
        Moderate  17 8.85% 
        Mild 6 3.13% 
        Minimal 58 30.2% 
        No depression 93 48.4% 
Distress Scores    
        Positive Distress  102 53.1% 
35 
        Negative Distress  90 46.9% 
Answer to Self Harm 
Question    
         Positive 
 21 28.0% 
         Negative  54 72.0% 
 
 
Table 5: Description of Sample by Depression Score Categories (N=5,576) 
     
Depression 





(N, %)  
Minimal 
depressio
n (N, %)  
Mild 
depression  
(N, %)  
Moderate 
depression 




(N, %)  
Severe 
Depression 
(N, %)            
P Value (Fisher Exact 
Test)  
Age (years)           




(6.56%) 7 (7.53%) 9 (9.57%) 4 (7.84%) 2 (10.5%)  <0.001 




(41.3%) 41 (44.1%) 34 (36.2%) 25 (49.0%) 10 (52.6%)   




(44.8%) 35 (37.6%) 46 (48.9%) 20 (39.2%) 7 (36.8%)   




(7.34%) 10 (10.8%) 5 (5.32%) 2 (2.62%) 0 (0.00%)   
Sex          




(12.8%) 15 (16.1%) 12 (12.7%) 9 (17.7%) 4 (21.1%)  <0.001 




(87.2%) 78 (83.8%) 82 (87.2%) 
42 
(82.35%) 15 (78.9%)   
Race          





(81.0%) 73 (78.5%) 66 (70.2%) 38 (74.5%) 13 (68.4%)  <0.001 
       Black or 





(8.12%) 14 (15.1%) 9 (9.57%) 4 (7.84%) 1 (5.26%)   
36 
      Asian 
 69  
(1.56%) 
23 
(2.56%) 2  (2.15%) 5 (5.32%) 2 (3.92%) 0 (0.00%)   




(4.45%) 2 (2.15%) 11 (11.7%) 5 (9.80%) 3 (15.8%)   




(3.89%) 2 (2.15%) 3 (3.19%) 2 (3.92%) 2 (10.5%)   
Cancer Type         <0.001 




(34.3%) 53 (57.0%) 57 (60.6%) 24 (47.1%) 9 (47.4%)   






(1.56%) 2 (2.15%) 0 (0.00%) 0 (0.00%) 0 (0.00%)   





(1.22%) 0 (0.00%) 1 (1.06%) 0 (0.00%) 0 (0.00%)   





(2.00%) 1 (1.08%) 3 (3.19%) 2 (3.92%) 0 (0.00%)   




(1.45%) 1 (1.08%) 2 (2.13%) 0 (0.00%) 1 (5.26%)   
      Colon Cancer 
51 
(1.15%) 8 (0.89%) 1 (1.08%) 1 (1.06%) 0 (0.00%) 0 (0.00%)   





(34.3%) 35 (37.6%) 30 (31.9%) 25 (49.0%) 9 (47.4%)   
Time Since 
Diagnosis        <0.001 






(19.2%) 6 (6.45%) 6 (6.38%) 12 (25.5%)` 3 (15.8%)   






(80.8) 87 (93.6%) 88 (93.6%) 39 (76.5%) 16 (84.2%)   
Site          




(60.1%) 59 (63.4%) 59 (62.8%) 32 (62.8%) 11 (57.9%)   




(8.45%) 8 (8.60%) 13 (13.8%) 9 (17.7%) 3 (15.8%)   








Table 6: Distribution of Distress Scores (N=5,396) 
   
Distress 




(N, %)  
Positive 
Distress 
(N, %)  P-value 
Age (years)     <0.001 
    25-44 
202 
(4.62%) 72 (7.41%)  
    45-64 
1549 
(35.4%) 488 (48.9%)  
    65-84 
2254 
(51.6%) 392 (39.2%)  
    85+ 
367 
(8.39%) 45 (4.50%)  
Sex   <0.001 
      Male 
938 
(21.5%) 103 (10.3%)  
       Female  
3433 
(78.5%) 896 (89.7%)  
Race   <0.001 
        White  
2022 
(83.04%) 1647 (85.0%)  
       Black or African         
American  
135 
(5.54%) 107 (5.52%)  
        Asian 40 (1.64%) 37 (1.91%)  
        Other 77 (3.16%) 6 (3.20%)  
        Patient Refused 
161 
(6.61%) 84 (4.34%)  
Cancer Type    <0.001 
         Breast Cancer  
2191 
(50.1%) 308 (30.8%)  
38 
        Chronic lymphocytic 
leukemia  
148 
(3.39%) 15 (1.50%)  
       Malignant Melanoma 81 (1.85%) 13 (1.30%)  
       Prostate Cancer  
100 
(2.29%) 5 (0.50%)  
       Myeloma  83 (1.90%) 5 (0.00%)  
Colon Cancer  69 (1.58%) 1 (0.10%)  
        All other cancer 
types 
1700 
(38.9%) 308 (30.8%)  
Time Since Diagnosis   <0.001 
       More than 6 months 
since diagnosis  
627 
(14.3%) 129 (12.9%)  
       Less than 6 months 
since diagnosis 
3745 
(85.7%) 870 (87.1%)  
Site    <0.001 
Smilow 
1870 
(42.8%) 681 (68.2%)  
Torrington  
1112 
(25.4%) 100 (10.0%)  
Guilford  
1390 
(31.8%) 218 (21.8%)  
    
 
 
Table 7: Unadjusted Associations Between Study Variables and Positive Self-harm Scores (N=62) 
Characteristic Na 




Age (years)      
     25-44 54 8 (14.8%) 1.00 
39 
     45-64 263  17 (6.46%) 0.63 (0.16-2.43) 
     65-84  323 30 (8.75%) 0.66 (0.18-2.46) 
     85+ 61 7 (11.5%) 0.53 (0.08-3.49) 
Sex    
       Female 568 46 (8.10%) 0.61 (0.28-1.33) 
       Male 153 16 (10.5%) 1.00 
Race    
        Black or 
African         
American  60 3 (5.00%) 0.37 (0.05-2.84) 
       Asian     17 3 (17.7%) 3.46 (0.67-18.0) 
        Other 31  4 (16.1%) 1.48 (0.32-6.89) 
        Patient 
Refused  26 6 (23.1%) 3.46 (0.88-13.6) 
      White or 
Caucasian  587 45 (7.67%) 1.00 (1.00) 
Cancer Type     
         Breast 
Cancer  334 29 (8.68%) 1.14 (0.54-2.41) 
        Chronic 
lymphocytic 
leukemia  16 1 (6.25%) 
<0.001* (<0.001-
>999.9) 
       Malignant 
Melanoma  11 0 (0.00%) 
<0.001* (<0.001-
>999.9) 
       Prostate 
Cancer       9 4 (44.4%) 10.4 (1.91-56.2) 
       Myeloma 25 1 (4.00%) 
<0.001* (<0.001-
>999.9) 
Colon Cancer  10 1 (4.00%) 1.73 (0.19-15.4) 
40 
Other cancers  316 26 (8.23%) 1.00 (1.00) 
Time Since 
Diagnosis    
       More than 6 
months since 
diagnosis  207 16 (7.73%) 0.91 (0.41-2.01) 
       Less than 6 
months since 
diagnosis 
 514 46 (8.95%) 1.00 
Site     
       Smilow 354 36 (10.2%) 1.00 
                            
Torrington  81 14 (17.3%) 3.24 (1.39-7.54)** 
       Guilford 286 12 (4.20%) 0.32 (0.12-0.89)** 
Depression 
Scores    
   Severe  18 6 (33.3%) 10.3 (2.11-49.9)** 
   Moderately  
Severe  49 10 (20.4%) 6.84 (2.14-21.9)** 
   Moderate  86 11 (12.8%) 2.85 (0.95-8.52) 
    Mild 79 3 (3.80%) 0.40 (0.05-3.23) 
   Minimal 185 15 (8.11%) 2.08 (0.79-5.46) 
  No depression 304 17 (5.59%) 1.00 
Distress Scores     
  Positive Distress  255 36 (14.1%) 2.16 (1.06-4.40)** 
  Negative Distress  466 26 (5.58%) 1.00 
 
*Large confidence intervals due to quasi-complete separation  
41 
**Statistically Significant  
 
 
Table 8: Multivariable logistic regression model on Validated Dataset of Factors Associated with Thoughts of Self-Harm 
Characteristic Adjusted Odds Ratio (95% CI) P-value 
Gender     
     Female 0.40 (0.12-1.32) 0.13 
Site   
      Torrington 2.18 (0.78-6.12) 0.14 
      Guilford 0.17 (0.05-0.66) 0.01* 
Depression scores   
       Severe 8.23 (1.72-39.3) 0.01* 
      Moderately 
severe  3.72 (1.24-11.2) 0.02* 
 Cancer Type   
       Prostate 7.55 (0.96-59.6) 0.06 
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